PAP Device AHI Underestimates Sleep Apnea

A new study challenges the standard practice of using residual apnea-hypopnea index (AHI) data from positive airway pressure (PAP) devices to gauge treatment success. Research discussed on the American Academy of Sleep Medicine's Talking Sleep podcast indicates these device-reported metrics may significantly underestimate a patient's true disease burden.

Dr. Sahil Chopra compared PAP-downloaded residual AHI to objective measurements from cardiopulmonary coupling (CPC) analysis. The discrepancy was substantial. The mean residual AHI from PAP downloads was 2.4, while the CPC-derived AHI averaged 12.1. Even more concerning, 85% of nights that showed a residual AHI under 5 on PAP downloads had an elevated AHI when measured objectively.

Why PAP Downloads May Be Misleading

Dr. Chopra explained several reasons PAP devices might systematically underestimate residual sleep apnea. Mask leak is a primary factor. Unstable breathing patterns and periodic breathing can also interfere with the device's ability to accurately score events. The algorithm within PAP machines is designed for therapy delivery, not necessarily for precise diagnostic scoring of residual respiratory events.

For his study, Dr. Chopra used cardiopulmonary coupling as the objective comparator metric. This analysis was performed using data from a photoplethysmography (PPG)-based wearable ring that patients wore for seven to ten nights. This method provides an independent assessment of sleep-disordered breathing beyond the PAP machine's own reporting.

The Hidden Risk of Residual Hypoxia

A critical finding involved residual hypoxia, a measure not typically provided by standard PAP downloads. Dr. Chopra discovered a significant hypoxic burden in many patients who were considered "well-treated" by conventional PAP AHI standards. This is clinically important because hypoxic burden, not just the AHI number, is a key driver of cardiovascular risk associated with sleep apnea.

This hidden hypoxia means patients might be told their therapy is effective based on a low device-reported AHI, while still experiencing physiological stress that could contribute to long-term health consequences.

Clinical Implications and Next Steps

The conclusion is not that PAP-derived AHI is useless, but that it should not be the sole metric for assessing treatment efficacy. Dr. Chopra emphasized that even patients who report feeling good symptomatically may have significant residual respiratory events and hypoxia that standard PAP downloads fail to detect.

The clinical applications discussed include guidance on when a clinician should pursue objective testing. This might be considered for patients with persistent symptoms despite apparently good PAP data, or for those with high cardiovascular risk profiles. When objective testing reveals inadequate disease control despite an acceptable PAP-reported AHI, interventions can be adjusted. These might include optimizing pressure settings, addressing mask fit to reduce leak, or exploring different therapy modes.

Dr. Sahil Chopra is a physician quadruple board-certified in Sleep Medicine, Pulmonary and Critical Care Medicine, and Internal Medicine. His clinical philosophy centers on objective measurement and continuous physiologic assessment rather than relying on single-night testing and device-reported metrics. His research advocates for multi-night measurement to fully characterize treatment response in sleep apnea.

This discussion provides an essential perspective for clinicians who rely on PAP downloads to manage patients. It highlights the potential need for supplementary objective home diagnostics to ensure sleep apnea is truly well-controlled, moving beyond the assumption that a low device-reported AHI tells the whole story.